From €3652EUR$3,990USD£3,104GBP
From €3652EUR$3,990USD£3,104GBP
From €1918EUR$2,095USD£1,630GBP
€3652EUR$3,990USD£3,104GBP
- Report
- May 2025
North America
From €1918EUR$2,095USD£1,630GBP
€3652EUR$3,990USD£3,104GBP
- Report
- May 2025
Middle East
From €1918EUR$2,095USD£1,630GBP
€3652EUR$3,990USD£3,104GBP
- Report
- May 2025
Asia Pacific
From €1918EUR$2,095USD£1,630GBP
€3652EUR$3,990USD£3,104GBP
From €1918EUR$2,095USD£1,630GBP
€3652EUR$3,990USD£3,104GBP
From €1918EUR$2,095USD£1,630GBP
€3652EUR$3,990USD£3,104GBP
- Report
- May 2025
United States
From €1918EUR$2,095USD£1,630GBP
€3652EUR$3,990USD£3,104GBP
- Report
- May 2025
United Kingdom
From €1918EUR$2,095USD£1,630GBP
€3652EUR$3,990USD£3,104GBP
The Blood Fractions market within the context of Coagulation and Hemostasis Testing is a segment of the in-vitro diagnostics industry. It is composed of products used to diagnose and monitor bleeding and clotting disorders. These products include reagents, instruments, and consumables used to measure the activity of clotting factors, platelet function, and fibrinolytic activity. The market is driven by the increasing prevalence of bleeding and clotting disorders, as well as the growing demand for point-of-care testing.
The Blood Fractions market is highly competitive, with a number of large and small companies offering a variety of products. Some of the major players in the market include Siemens Healthineers, Roche Diagnostics, Abbott Laboratories, Sysmex Corporation, and Grifols. Show Less Read more